Business Wire
- Business Wire
Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol® for the Treatment of Dry Eye Disease
PDUFA target action date is June 8, 2023 HEIDELBERG, Germany, and CAMBRIDGE, MA, USA–(BUSINESS WIRE)–#cyclasol–Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that…
Read More »